The study, known as the Apixaban versus Acetylsalicylic Acid to Prevent Strokes in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, ...

Observational data suggest apixaban leads to fewer thromboembolic events but higher bleeding risk, highlighting the need for individualized decision-making in dialysis patients.

In everyday practice, patients with atrial fibrillation or flutter who are newly started on apixaban (Eliquis; Bristol-Myers Squibb) have lower ischemic and bleeding risks compared with those started ...

Paying Patients to Access the Nation’s #1 Prescribed Oral Blood ThinnerPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Eliquis--The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) — (Pfizer NYSE: PFE) Alliance ...

Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...

There is a lot of drug switching that's happening, whether it's for medical or nonmedical reasons, said Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, ...

The factor Xa inhibitor apixaban is noninferior to conventional therapy with enoxaparin and a vitamin K antagonist in patients with acute venous thromboembolism (VTE). The study, published online July ...

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during 3-month trial period. HealthDay News — The risk for clinically relevant bleeding is significantly ...

The ADOPT trial investigators have reported that 30 days of apixaban thromboprophylaxis is associated with a similar 30-day rate of death related to venous thromboembolism, pulmonary embolism, ...

Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. The trial was terminated ...